Investors of Regeneron Pharmaceuticals Have Chance to Lead in Securities Fraud Case

Lead Your Voice in Regeneron's Securities Fraud Class Action

Current investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have an opportunity to take a proactive role in a significant securities fraud lawsuit against the company. The Rosen Law Firm, renowned for its advocacy on behalf of investors, has formally reminded securities purchasers of Regeneron between November 2, 2023, and October 30, 2024, of critical deadlines approaching for participation in this class action suit.

The official deadline for investors wishing to serve as lead plaintiffs is set for March 10, 2025. A lead plaintiff acts as a spokesperson for the other class members and focuses on guiding litigation strategy moving forward. If you purchased Regeneron securities during the specified class period, you could qualify for participation in potential compensation without upfront costs, thanks to a contingency fee model. This means you only pay if a recovery is made.

How to Get Involved

To join the class action, interested investors can visit Rosen Law Firm's website, where detailed instructions are provided. Additionally, potential plaintiffs can reach out directly to Phillip Kim, Esq., toll-free at 866-767-3653, or via email at [email protected] for further assistance and inquiries.

Prior to investors considering joining the action, it’s essential to understand that a lawsuit has been filed but no class has yet been certified. Until such progression, individuals are not formally represented unless they engage an attorney.

Facts on the Case

The lawsuit alleges serious claims against Regeneron, indicating that throughout the specified class period, the company made statements that were both false and misleading. Details surrounding key Eylea sales practices, particularly regarding credit card fee payments made to distributors, come under scrutiny. This supposed shrouding of actual practices not only impacted the competitive edge but also resulted in misleading positives regarding Eylea’s sales figures.

Key allegations include that Regeneron stealthily managed to lower Eylea’s selling price through undisclosed financial arrangements, thus misrepresenting how their product pricing related to its competition. This led to inflated sales reports and a lack of transparency concerning the actual Average Sales Price reported to federal agencies, potentially breaching the False Claims Act.

The Rosen Law Firm's Reputation

The Rosen Law Firm has a proven track record in handling securities class actions, and investors are urged to choose their legal counsel carefully, aiming for firms with tangible experience in such litigation. Rosen Law has secured significant settlements in the past, demonstrating reliability and resolve in championing investors' rights. Notably, the firm has consistently been ranked within the top 4 in terms of securities class action settlements over several years, including a landmark $438 million recovery in just 2019.

Future Steps

Investors planning to join the class action should do so promptly—during the timeframe leading up to the stipulated deadline—if they wish to lead the charge against Regeneron. This class action serves not only as a potential avenue for compensation but also as a means to hold corporations accountable for their disclosed practices and statements that directly affect their investor base.

For ongoing updates or inquiries, follow the Rosen Law Firm's social media channels on platforms like LinkedIn, Twitter, and Facebook.

Together, through collective action, Regeneron’s investors can voice their concerns and push for the accountability they rightfully deserve.